Alendronic Acid 10 Mg Tablets
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Alendronic Acid 10 mg tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 10 mg alendronic acid (equivalent to 13.052 mg of sodium alendronate trihydrate).
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet
White to off-white, round, biconvex, uncoated tablets debossed with ‘F’ on one side and ‘18’ on the other side. The tablets are 5 mm in diameter.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
- Treatment of postmenopausal osteoporosis. Alendronic acid reduces the risk of vertebral and hip fractures.
- Treatment of osteoporosis in men at increased risk of fracture. A reduction in the incidence of vertebral, but not of non-vertebral fractures has been demonstrated.
- Prophylaxis of glucocorticoid-induced osteoporosis.
4.2 Posology and method of administration
For oral use.
The optimal duration of bisphosphonate treatment for osteoporosis has not been established. The need for continued treatment should be re-evaluated periodically based on the benefits and potential risks of alendronic acid on an individual patient basis, particularly after 5 or more years of use.
Treatment of osteoporosis in postmenopausal women The recommended dose is 10 mg per day.
Treatment of osteoporosis in men The recommended dose is 10 mg per day.
Prophylaxis of glucocorticoid-induced osteoporosis
For post-menopausal women who are not receiving oestrogen treatment the recommended dose is one 10 mg tablet daily.
To permit adequate absorption of alendronate:
Alendronic Acid must be taken at least 30 minutes before the first food, beverage, or medicinal product of the day with plain water only. Other beverages (including mineral water), food and some medicinal products are likely to reduce the absorption of alendronate (see sction 4.5).
To facilitate delivery to the stomach and thus reduce the potential for local and oesophageal irritation/adverse experiences (see section 4.4):
• Alendronic Acid should only be swallowed upon arising for the day with a full glass of water (not less than 200 ml).
• Patients should only swallow Alendronic Acid whole. Patients should not crush or chew the tablet or allow the tablet to dissolve in their mouths because of a potential for oropharyngeal ulceration.
• Patients should not lie down until after their first food of the day which should be at least 30 minutes after taking the tablet.
• Patients should not lie down for at least 30 minutes after taking Alendronic Acid.
• Alendronic Acid should not be taken at bedtime or before arising for the day.
Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate (see section 4.4).
Use in the elderly: In clinical studies there was no age-related difference in the efficacy or safety profiles of alendronate. Therefore no dosage adjustment is necessary for the elderly.
Use in renal impairment: No dosage adjustment is necessary for patients with GFR greater than 35 ml/min. Alendronate is not recommended for patients with renal impairment where GFR is less than 35 ml/min, due to lack of experience.
Paediatric patients: Alendronate sodium is not recommended for use in children under the age of 18 years due to insufficient data on safety and efficacy in conditions associated with paediatric osteoporosis (also see section 5.1).
4.3 Contraindications
• Abnormalities of the oesophagus and other factors which delay oesophageal emptying such as stricture or achalasia.
• Inability to stand or sit upright for at least 30 minutes.
• Hypersensitivity to alendronate or to any of the excipients listed in section 6.1.
• Hypocalcaemia.
• See also section 4.4 ‘Special warnings and precautions for use’.
4.4 Special warnings and precautions for use
Alendronate can cause local irritation of the upper gastro-intestinal mucosa. Because there is a potential for worsening of the underlying disease, caution should be used when alendronate is given to patients with active upper gastro-intestinal problems, such as dysphagia, oesophageal disease, gastritis, duodenitis, ulcers, or with a recent history (within the previous year) of major gastro-intestinal disease such as peptic ulcer, or active gastro-intestinal bleeding, or surgery of the upper gastrointestinal tract other than pyloroplasty (see section 4.3). In patients with known Barrett's oesophagus, prescribers should consider the benefits and potential risks of alendronate on an individual patient basis.
Oesophageal reactions (sometimes severe and requiring hospitalisation), such as oesophagitis, oesophageal ulcers and oesophageal erosions, rarely followed by oesophageal stricture, have been reported in patients receiving alendronate. Physicians should therefore be alert to any signs or symptoms signalling a possible oesophageal reaction and patients should be instructed to discontinue alendronate and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing or retrosternal pain, new or worsening heartburn.
The risk of severe oesophageal adverse experiences appears to be greater in patients who fail to take alendronate properly and/or who continue to take alendronate after developing symptoms suggestive of oesophageal irritation. It is very important that the full dosing instructions are provided to, and understood by the patient (see section 4.2). Patients should be informed that failure to follow these instructions may increase their risk of oesophageal problems.
While no increased risk was observed in extensive clinical trials, there have been rare (postmarketing) reports of gastric and duodenal ulcers, some severe and with complications.
Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection (including osteomyelitis) has been reported in patients with cancer receiving treatment regimens including primarily intravenously administered bisphosphonates. Many of these patients were also receiving chemotherapy and corticosteroids. Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphosphonates.
The following risk factors should be considered when evaluating an individual’s risk
of developing osteonecrosis of the jaw:
• (e.g., potency of the bisphosphonate (highest for zoledronic acid), route of administration (see above), and cumulative dose in cancer patients).
• Concomitant risk factors include cancer, chemotherapy, radiotherapy, corticosteroids, smoking,
• a history of dental disease, including poor oral hygiene, periodontal disease, dental trauma, invasive dental procedures, and poorly fitting dentures)
A dental examination with appropriate preventive dentistry should be considered prior to treatment with oral bisphosphonates in patients with poor dental status.
While on treatment, these patients should avoid invasive dental procedures if possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.
During bisphosphonate treatment, all patients should be encouraged to maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms such as dental mobility, pain, or swelling.
Atypical fractures of the femur
Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis. These transverse or short oblique fractures can occur anywhere along the femur from just below the lesser trochanter to just above the supracondylar flare. These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. Fractures are often bilateral; therefore the contralateral femur should be examined in bisphosphonate-treated patients who have sustained a femoral shaft fracture. Poor healing of these fractures has also been reported. Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment.
During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture.
Bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates. In postmarketing experience, these symptoms have rarely been severe and/or incapacitating (see section 4.8).
The time to onset of symptoms varied from one day to several months after starting treatment. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate.
In post-marketing experience, there have been rare reports of severe skin reactions including Stevens Johnson syndrome and toxic epidermal necrolysis.
Alendronate is not recommended for patients with renal impairment where GFR is less than 35 ml/min, (see section 4.2).
Causes of osteoporosis other than oestrogen deficiency and ageing should be considered.
Hypocalcaemia must be corrected before initiating therapy with alendronate (see section 4.3).
Other disorders affecting mineral metabolism (such as vitamin D deficiency and hypoparathyroidism) should also be effectively treated. In patients with these conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with Alendronic Acid.
Due to the positive effects of alendronate in increasing bone mineral, decreases in serum calcium and phosphate may occur especially in patients taking glucocorticoids in whom calcium absorption may be decreased. These are usually small and asymptomatic. However, there have been rare reports of symptomatic hypocalcemia, which have occasionally been severe and often occurred in patients with predisposing conditions (e.g. hypoparathyroidism, vitamin D deficiency and calcium malabsorption). Ensuring adequate calcium and vitamin D intake is particularly important in patients receiving glucocorticoids.
4.5 Interaction with other medicinal products and other forms of interaction
If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product (see sections 4.2 and 5.2).
No other interactions with medicinal products of clinical significance are anticipated. A number of patients in the clinical trials received oestrogen (intravaginal, transdermal, or oral) while taking alendronate. No adverse experiences attributable to their concomitant use were identified.
Since NSAID use is associated with gastrointestinal irritation, caution should be used during concomitant use with alendronate.
Although specific interaction studies were not performed, in clinical studies alendronate was used concomitantly with a wide range of commonly prescribed medicinal products without evidence of clinical adverse interactions.
4.6 Fertility, pregnancy and lactation
Use during pregnancy
Alendronate should not be used during pregnancy. There are no adequate data from the use of alendronate in pregnant women. Animal studies do not indicate direct harmful effects with respect to pregnancy, embryonal/fetal development, or postnatal development. Alendronate given during pregnancy in rats caused dystocia related to hypocalcemia (see section 5.3).
Use during lactation
It is not known whether alendronate is excreted into human breast milk. Alendronate should not be used by breast-feeding women.
4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed. However, certain adverse reactions that have been reported with Alendronic Acid may affect some patients ability to drive or operate machinery. Individual responses to Alendronic Acid may vary. (See section 4.8).
4.8 Undesirable effects
In a one-year study in post-menopausal women with osteoporosis the overall safety profiles of Alendronate sodium (‘Fosamax®’) Once Weekly 70 mg (n=519) and alendronate 10 mg/day (n=370) were similar.
In two three-year studies of virtually identical design, in post-menopausal women (alendronate 10 mg: n=196, placebo: n=397) the overall safety profiles of alendronate 10 mg/day and placebo were similar.
Adverse experiences reported by the investigators as possibly, probably or definitely drug-related are presented below if they occurred in >1% in either treatment group in the one-year study, or in >1% of patients treated with alendronate 10 mg/day and at a greater incidence than in patients given placebo in the three-year studies:
|
One-Year Study |
Three-Year Studies | |||
|
Alendroninc |
Alendronic |
Alendronic |
Placebo | |
|
acid 70 mg (n = 519) % |
acid 10 mg/day (n = 370) % |
acid 10 mg/day (n = 196) % |
(n = 397) % | |
|
Gastrointestinal |
3.7 |
3.0 |
6.6 |
4.8 |
|
disorders |
2.7 |
2.2 |
3.6 |
3.5 |
|
abdominal pain |
1.9 |
2.4 |
2.0 |
4.3 |
|
dyspepsia |
1.9 |
2.4 |
3.6 |
4.0 |
|
acid regurgitation |
1.0 |
1.4 |
1.0 |
0.8 |
|
nausea |
0.8 |
1.6 |
3.1 |
1.8 |
|
abdominal distention |
0.6 |
0.5 |
3.1 |
1.8 |
|
constipation |
0.4 |
0.5 |
1.0 |
0.0 |
|
diarrhoea |
0.4 |
1.6 |
2.6 |
0.5 |
|
dysphagia |
0.2 |
1.1 |
0.5 |
1.3 |
|
flatulence |
0.0 |
1.1 |
0.0 |
0.0 |
|
gastritis |
0.0 |
0.0 |
1.5 |
0.0 |
|
oesophageal ulcer | ||||
|
Musculoskeletal, | ||||
|
connective tissue and | ||||
|
bone disorders |
2.9 |
3.2 |
4.1 |
2.5 |
|
musculoskeletal (bone, | ||||
|
muscle or joint) pain |
0.2 |
1.1 |
0.0 |
1.0 |
|
muscle cramp | ||||
|
Nervous system disorders | ||||
|
headache |
0.4 |
0.3 |
2.6 |
1.5 |
The following adverse experiences have also been reported during clinical studies and/or postmarketing use:
[Very common (>1/10), Common (>1/100, <1/10), Uncommon (>1/1,000, <1/100), Rare (>1/10,000, <1/1,000), Very rare (<1/10,000 including isolated cases)
|
Immune system disorders: |
Rare: hypersensitivity reactions including urticaria and angioedema |
|
Metabolism and nutrition disorders: |
Rare: symptomatic hypocalcaemia, often in association with predisposing conditions. § |
|
Nervous system disorders: |
Common: headache, dizzinessT Uncommon: dysgeusia^ |
|
Eye disorders: |
Uncommon: eye inflammation (uveitis, scleritis, episcleritis) |
|
Ear and labyrinth disorders |
Common: vertigo T |
|
Gastrointestinal disorders: |
Common: abdominal pain, dyspepsia, constipation, diarrhoea, flatulence, oesophageal ulcer*, dysphagia*, abdominal distension, acid regurgitation |
|
Uncommon: nausea, vomiting, gastritis, oesophagitis*, oesophageal erosions*, melena1 Rare: oesophageal stricture*, oropharyngeal ulceration*, upper gastrointestinal PUBs (perforation, ulcers, bleeding)§ | |
|
Skin and subcutaneous tissue disorders: |
Common: alopecia1) pruritus1 Uncommon: rash,erythema Rare: rash with photosensitivity, severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis* |
|
Musculoskeletal, connective tissue and bone disorders: |
Very common: musculoskeletal (bone, muscle or joint) pain which is sometimes severe1§ Common: joint swelling1 Rare: Osteonecrosis of the jaw*§, atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction) |
|
General disorders and administration site conditions: |
Common: asthenia1, peripheral oedema1 Uncommon: transient symptoms as in an acute-phase response (myalgia, malaise and rarely, fever), typically in association with initiation of treatment. |
§ See section 4.4
1Frequency in Clinical Trials was similar in the drug and placebo group.
*See sections 4.2 and 4.4
*This adverse reaction was identified through post-marketing surveillance. The frequency of rare was estimated based on relevant clinical trials
Identified in postmarketing experience.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard
4.9 Overdose
Hypocalcaemia, hypophosphataemia and upper gastro-intestinal adverse events, such as upset stomach, heartburn, oesophagitis, gastritis, or ulcer, may result from oral overdosage.
No specific information is available on the treatment of overdosage with alendronate. Milk or antacids should be given to bind alendronate. Owing to the risk of oesophageal irritation, vomiting should not be induced and the patient should remain fully upright.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Bisphosphonate, for the treatment of bone diseases.
ATC Code: M05B A04
Alendronic acid is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. The bone formed during treatment with alendronic acid is of normal quality.
Treatment of post-menopausal osteoporosis
The effects of alendronic acid on bone mass and fracture incidence in postmenopausal women were examined in two initial efficacy studies of identical design (n=994) as well as in the Fracture Intervention Trial (FIT: n=6,459).
In the initial efficacy studies, the mean bone mineral density (BMD) increases with alendronic acid 10 mg/day relative to placebo at three years were 8.8%, 5.9% and 7.8% at the spine, femoral neck and trochanter, respectively. Total body BMD also increased significantly. There was a 48% reduction in the proportion of patients treated with alendronic acid experiencing one or more vertebral fractures relative to those treated with placebo. In the two-year extension of these studies BMD at the spine and trochanter continued to increase and BMD at the femoral neck and total body were maintained.
FIT consisted of two placebo-controlled studies: a three-year study of 2,027 patients who had at least one baseline vertebral (compression) fracture and a four-year study of 4,432 patients with low bone mass but without a baseline vertebral fracture, 37% of whom had osteoporosis as defined by a baseline femoral neck BMD at least 2.5 standard deviations below the mean for young, adult women. In all FIT patients with osteoporosis from both studies, alendronic acid reduced the incidence of: >1 vertebral fracture by 48%, multiple vertebral fractures by 87%, >1 painful vertebral fracture by 45%, any painful fracture by 31% and hip fracture by 54%.
Overall these results demonstrate the consistent effect of alendronic acid to reduce the incidence of fractures, including those of the spine and hip, which are the sites of osteoporotic fracture associated with the greatest morbidity.
Prevention of post-menopausal osteoporosis
In a two-year and a three- year studies, in women being at least 6 months post-menopausaland aged 60, prevention of bone loss has been proven. As expected the loss of BMD in spine, hip (femoral neck and trochanter) and body as a whole was 1% per year. Whereas alendronate 5 mg per day maintained an effective prevention of the bone loss and induced a significant increase in bone mass in each of these places. The average increase in BMD versus base line in the lumbal spine femoral neck, trochanter and body as a whole at the end of the two-year investigation were 3.46%, 1.27%, 2.98% and 0.67% respectively and at the end of the threeyear study 2.89%, 1.10%, 2.71% and 0,32% respectively. Moreover, alendronate 5 mg reduces bone loss by approximately half in the lower arm in comparison with placebo. Alendronate 5 mg was effective in this population independently of age, time after menopause, race and speed of bone metabolism at the beginning of treatment. In the 28 patients receiving dosages of alendronate up to 10 mg per day and who had taken a biopsy, they all showed normal bone histology.
Concomitant use with oestrogen/hormone replacement therapy (HRT)
The effects on BMD of treatment with alendronic acid tablet 10 mg once-daily and conjugated oestrogen (0.625 mg/day) either alone or in combination were assessed in a two-year study of hysterectomised, post-menopausal, osteoporotic women. At two years, the increases in lumbar spine BMD from baseline were significantly greater with the combination (8.3%) than with either oestrogen or alendronic acid tablet alone (both 6.0%).
The effects on BMD when alendronic acid tablet was added to stable doses (for at least one year) of HRT (oestrogen ± progestin) were assessed in a one-year study in post-menopausal, osteoporotic women. The addition of alendronic acid tablet 10 mg once-daily to HRT produced, at one year, significantly greater increases in lumbar spine BMD (3.7%) vs. HRT alone (1.1%). In these studies, significant increases or favourable trends in BMD for combined therapy compared with HRT alone were seen at the total hip, femoral neck and trochanter. No significant effect was seen for total body BMD.
Treatment of osteoporosis in men
The efficacy of alendronic acid tablet 10 mg once daily in men (ages 31 to 87; mean, 63) with osteoporosis was demonstrated in a two-year study. At two years, the mean increases relative to placebo in BMD in men receiving alendronic acid tablet 10 mg/day were: lumbar spine, 5.3%; femoral neck, 2.6%; trochanter, 3.1%; and total body, 1.6%. Alendronic acid tablet was effective regardless of age, race, gonadal function, baseline rate of bone turnover, or baseline BMD. Consistent with much larger studies in post-menopausal women, in these 127 men, alendronic acid tablet 10 mg/day reduced the incidence of new vertebral fracture (assessed by quantitative radiography) relative to placebo (0.8% vs. 7.1%) and, correspondingly, also reduced height loss (-0.6 vs. -2.4 mm).
Glucocorticoid-induced osteoporosis
The efficacy of alendronic acid tablet 5 and 10 mg once daily in men and women receiving at least 7.5 mg/day of prednisone (or equivalent) was demonstrated in two studies. At two years of treatment, spine BMD increased by 3.7% and 5.0% (relative to placebo) with alendronic acid tablet 5 and 10 mg/day respectively. Significant increases in BMD were also observed at the femoral neck, trochanter, and total body. In post-menopausal women not receiving oestrogen, greater increases in lumbar spine and trochanter BMD were seen in those receiving 10 mg alendronic acid tablet than those receiving 5 mg. Alendronic acid tablet was effective regardless of dose or duration of glucocorticoid use. Data pooled from three dosage groups (5 or 10 mg for two years or 2.5 mg for one year followed by 10 mg for one year) showed a significant reduction in the incidence of patients with a new vertebral fracture at two years (Alendronic acid 0.7% vs. placebo 6.8%).
Laboratory test findings
In clinical studies, asymptomatic, mild and transient decreases in serum calcium and phosphate were observed in approximately 18 and 10%, respectively, of patients taking alendronate 10 mg/day versus approximately 12 and 3% of those taking placebo. However, the incidences of decreases in serum calcium to < 8.0 mg/dl (< 2.0 mmol/l) and serum phosphate to < 2.0 mg/dl (< 0.65 mmol/l) were similar in both treatment groups.
Paediatric patients:
Alendronate sodium has been studied in a small number of patients with osteogenesis imperfecta under the age of 18 years. Results are insufficient to support the use of alendronate sodium in paediatric patients with osteogenesis imperfecta.
5.2 Pharmacokinetic properties
Absorption
The bioavailability of alendronic acid in women was 0.7% for doses ranging from 5 to 40 mg when administered after an overnight fast and two hours before a standardised breakfast. Oral bioavailability in men (0.6%) was similar to that in women. Bioavailability was decreased similarly to an estimated 0.46% and 0.39% when alendronate was administered one hour or half an hour before a standardised breakfast.
Administration of alendronic acid on one hour or half hour before a standardised breakfast gives a similar reduction in the bioavailability (approximately 40%). Under these circumstances, the total bioavailability is reduced to about 0.4%.
In osteoporosis studies, alendronic acid was effective when administered at least 30 minutes before the first food or beverage of the day.
Bioavailability was negligible whether alendronic acid was administered with, or up to two hours after, a standardised breakfast. Concomitant administration of alendronic acid with coffee or orange juice reduced bioavailability by approximately 60%.
In healthy subjects, oral prednisone (20 mg three times daily for five days) did not produce a clinically meaningful change in oral bioavailability of alendronic acid (a mean increase ranging from 20% to 44%).
Distribution
Studies in rats show that alendronic acid transiently distributes to soft tissues following 1 mg/kg intravenous administration but is then rapidly redistributed to bone or excreted in the urine. The mean steady-state volume of distribution, exclusive of bone, is at least 28 litres in humans. Concentrations of drug in plasma following therapeutic oral doses are too low for analytical detection (<5 ng/ml). Protein binding in human plasma is approximately 78%.
Biotransformation
There is no evidence that alendronic acid is metabolised in animals or humans.
Elimination
Following a single intravenous dose of [14C]alendronic acid, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces. Following a single 10 mg intravenous dose, the renal clearance of alendronic acid was 71 ml/min, and systemic clearance did not exceed 200 ml/min. Plasma concentrations fell by more than 95% within six hours following intravenous administration. The terminal half-life in humans is estimated to exceed ten years, reflecting release of alendronic acid from the skeleton. Alendronic acid is not excreted through the acidic or basic transport systems of the kidney in rats, and thus it is not anticipated to interfere with the excretion of other medicinal products by those systems in humans.
Characteristics in patients
Preclinical studies show that the drug that is not deposited in bone is rapidly excreted in the urine. No evidence of saturation of bone uptake was found after chronic dosing with cumulative intravenous doses up to 35 mg/kg in animals. Although no clinical information is available, it is likely that, as in animals, elimination of alendronic acid via the kidney will be reduced in patients with impaired renal function. Therefore, somewhat greater accumulation of alendronic acid in bone might be expected in patients with impaired renal function (see section 4.2).
5.3 Preclinical safety data
Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. Studies in rats have shown that treatment with alendronic acid during pregnancy was associated with dystocia in dams during parturition which was related to hypocalcaemia. In studies, rats given high doses showed an increased incidence of incomplete foetal ossification. The relevance to humans is unknown.
6.1 List of excipients
Cellulose, microcrystalline
Maize starch
Sodium starch glycolate (type A) Povidone (kollidon 30) Magnesium stearate
6.2 Incompatibilities
Not applicable
6.3 Shelf life
2 years
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container
The tablets are supplied in PVC/Aclar - Aluminium blister pack and HDPE tablet container pack.
Pack size:
PVC/Aclar - Aluminium blister pack: 10, 14, 20, 28, 30, 50, 56, 60, 84, 90, 98, 100, 112, 140 and 250 tablets
White opaque HDPE tablet container with white opaque polypropylene closure: 30, 50, 100, 250 and 1000 tablets
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements.
7 MARKETING AUTHORISATION HOLDER
Milpharm Limited
Ares, Odyssey Business Park, West End Road,
South Ruislip HA4 6QD.
United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 16363/0309
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
30/09/2014
10 DATE OF REVISION OF THE TEXT
30/09/2014